| Browse All

Atrium Therapeutics, Inc. (RNA)

Healthcare | Biotechnology | San Diego, United States | NasdaqGS
14.41 USD +0.38 (2.708%) ⇧ (April 17, 2026, 4 p.m. EDT)
After hours: 14.41

Short-term: ★☆☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 9, 2026, 12:25 a.m. EDT

RNA is a highly volatile and speculative stock with a negative earnings outlook, low liquidity, and a lack of dividend history. The stock has been trading near its 52-week low, indicating weak investor sentiment. The company is in the biotechnology sector, which is inherently risky, and its financial metrics, such as negative profit margins and a low current ratio, suggest significant financial distress. Given the lack of reliable earnings and the high risk associated with the industry, it is not advisable to invest in RNA for either short or long-term. The stock is not suitable for dividend investors either, as there is no history of dividend payouts.

None
Attribute Value
Sector Healthcare
Revenue per Share 1.2
Market Cap 223,570,672
Forward P/E -3.57
Profit Margins -265.88%
Website https://atriumtherapeutics.com

Info Dump

Attribute Value
52 Week Change -0.023050845
Address1 10,578 Science Center Drive
Address2 Suite 125
All Time High 16.77
All Time Low 11.95
Ask 14.5
Ask Size 1
Average Daily Volume10 Day 546,940
Average Daily Volume3 Month 1,039,842
Average Volume 1,039,842
Average Volume10Days 546,940
Bid 14.34
Bid Size 1
Book Value -4.042
City San Diego
Country United States
Crypto Tradeable 0
Currency USD
Current Price 14.41
Current Ratio 0.068
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 14.625
Day Low 13.99
Display Name Atrium Therapeutics
Earnings Timestamp End 1,778,533,200
Earnings Timestamp Start 1,778,533,200
Ebitda -49,308,000
Ebitda Margins -2.6484
Eps Forward -4.03333
Eps Trailing Twelve Months -4.48
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 13.947143
Fifty Day Average Change 0.46285725
Fifty Day Average Change Percent 0.03318653
Fifty Two Week Change Percent -2.3050845
Fifty Two Week High 16.77
Fifty Two Week High Change -2.3600006
Fifty Two Week High Change Percent -0.14072752
Fifty Two Week Low 11.95
Fifty Two Week Low Change 2.46
Fifty Two Week Low Change Percent 0.20585775
Fifty Two Week Range 11.95 - 16.77
Financial Currency USD
First Trade Date Milliseconds 1,772,202,600,000
Float Shares 15,036,174
Forward Eps -4.03333
Forward P E -3.5727303
Free Cashflow -11,653,375
Full Exchange Name NasdaqGS
Gmt Off Set Milliseconds -14,400,000
Gross Margins -1.37765
Gross Profits -25,649,000
Has Pre Post Market Data 1
Held Percent Insiders 0.0279
Held Percent Institutions 0.19198999
Implied Shares Outstanding 15,514,967
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,026-02-27
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Long Name Atrium Therapeutics, Inc.
Market us_market
Market Cap 223,570,672
Market State CLOSED
Max Age 86,400
Message Board Id finmb_1972622727
Most Recent Quarter 1,767,139,200
Net Income To Common -49,501,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 223,570,660
Number Of Analyst Opinions 1
Open 13.99
Operating Cashflow -41,129,000
Operating Margins -33.87893
Payout Ratio 0.0
Phone 619 876 0700
Post Market Change 0.0
Post Market Change Percent 0.0
Post Market Price 14.41
Post Market Time 1,776,456,605
Previous Close 14.03
Price Hint 2
Price To Book -3.5650668
Price To Sales Trailing12 Months 12.008307
Profit Margins -2.65877
Quick Ratio 0.002
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 0.38
Regular Market Change Percent 2.70848
Regular Market Day High 14.625
Regular Market Day Low 13.99
Regular Market Day Range 13.99 - 14.625
Regular Market Open 13.99
Regular Market Previous Close 14.03
Regular Market Price 14.41
Regular Market Time 1,776,456,000
Regular Market Volume 632,784
Return On Assets -3.99245
Revenue Growth -0.711
Revenue Per Share 1.2
Sand P52 Week Change 0.38150132
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 15,514,966
Shares Percent Shares Out 0.1233
Shares Short 1,184,615
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 432,798
Short Name Atrium Therapeutics, Inc.
Short Ratio 1.88
Source Interval 15
State CA
Symbol RNA
Target High Price 25.0
Target Low Price 25.0
Target Mean Price 25.0
Target Median Price 25.0
Total Debt 3,672,000
Total Revenue 18,618,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -4.48
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 13.947143
Two Hundred Day Average Change 0.46285725
Two Hundred Day Average Change Percent 0.03318653
Type Disp Equity
Volume 632,784
Website https://atriumtherapeutics.com
Zip 92,121